Aethon Therapeutics

Happening today at #AACR2026! Come learn about how Aethon is tackling KRAS amplification as an oncogenic driver and/or shared resistance mechanism through T cell engager targeting! Here we will share data on our novel, mutation agnostic target, “kAMP.A2.”

Excited to share that Lorenzo Maso, on behalf of Aethon Tx, will present a poster at the #AACR2026 Annual Meeting: “KRAS amplification creates a targetable pMHC antigen for T cell engager therapy to overcome KRAS inhibitor resistance.” We describe a bispecific T cell engager targeting a novel, mutation-agnostic KRAS pMHC antigen (kAMP.A2) presented on HLA-A*02:01. KRAS amplification creates a selective therapeutic window—further enhanced by KRAS inhibition—enabling potent and specific tumor cell killing across models. Looking forward to sharing more at AACR.

Founded in 2022, Aethon Therapeutics is pioneering a novel immuno-oncology paradigm: creating neoantigens by design. The company’s proprietary HapImmune™ platform enables the generation of tumor-specific “synthetic neoantigens”, which will be presented on the tumor cell surface and then be selectively recognized by engineered antibodies. As the Chief Technology Officer, Dr. Christoph Rader will share his insights at the ChAbS 2026 Annual Conference, with title “Linking targeted therapy to immunotherapy by creating and targeting synthetic neoantigens in cancer.” Prior to joining the company, Dr. Christoph Rader research in Scripps Research, the National Cancer Institute (NCI) (Bethesda, MD), and University of Florida (Jupiter, FL) focused on developing and applying antibody engineering and conjugation technologies to antibody drug and target discovery for cancer therapy. At ChAbS' 2026 annual conference, Dr. Rader will share how synthetic neoantigen strategies can bridge targeted therapy with immunotherapy—offering a powerful new direction for precision oncology. We look forward to an exciting and insightful presentation! #ChineseAntibodySociety #ChAbS2026 #AntibodyEngineering  #Immunotherapy #CancerResearch #ChemicalBiology #DrugDiscovery #TranslationalScience #ChAbS

👍 We are pleased to spotlight this exciting new paper in Nature Communications titled “Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy.” Covalent inhibitors like sotorasib create uniquely tumor-specific, drug-modified peptides (synthetic neoantigens) presented by MHC molecules—but typically at extremely low copy numbers. To overcome this hurdle, researchers engineered novel bispecific T-cell engagers that bind these haptenated complexes with remarkable affinity. This innovative strategy offers a highly promising blueprint for bridging the gap between targeted small-molecule therapies and potent immunotherapy. Congratulations to first author Lorenzo Maso, corresponding authors Christoph Rader and Lauren Stopfer, and their team at the Aethon Therapeutics. 📖 Read the open access paper: https://lnkd.in/eW_AXujS 📢We are deeply honored to have Dr. Christoph Rader presenting as a Distinguished Speaker at our society's 2026 annual conference. Don't miss this opportunity to connect with him and other leaders in the field! 📅May 09, 2026, 1:00 PM EDT – May 10, 2026, 6:00 PM EDT 📍Boston Marriott Cambridge, 50 Broadway, Cambridge, MA 02142, USA 🔗Register now for the conference at our society’s official website: https://lnkd.in/eJkSxPxx #Antibody #Antibodies #AntibodyDiscovery #AntibodyDevelopment #AntibodyEngineering #AntibodyTherapeutics #Immunotherapy #KRAS #ProteinEngineering #TCellEngagers #Oncology #DrugDevelopment #Biotech

We’re excited to share that our new study, “Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy,” is now published in Nature Communications (open access link below).  Using targeted immunopeptidomics, we directly identified and quantified drug-modified KRASG12C neoantigens and engineered bispecific T cell engagers (AETX-R114 and AETX-R302) that recognize these haptenated peptides with high specificity across multiple HLA supertypes. This work advances our HapImmune™ platform and was performed in partnership with researchers at NYU. https://lnkd.in/eW_AXujS

Excited to speak at Ras-Targeted Drug Development next week on behalf of Aethon Therapeutics! Sharing highlights from our KRAS hapten-targeting TCEs + unveiling a new program against a novel KRAS MHC antigen. #KRAS #Immunotherapy #TCellEngagers #OncologyResearch #DrugDevelopment #Biotech